Trials / Unknown
UnknownNCT05663411
A Study of SHR6508 in Secondary Hyperparathyroidism
An Open-label, Randomized, Active-Controlled Dose Titration Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR6508 | SHR6508 |
| DRUG | SHR6508 | SHR6508 |
| DRUG | Cinacalcet | Cinacalcet |
Timeline
- Start date
- 2023-02-24
- Primary completion
- 2023-10-31
- Completion
- 2023-11-30
- First posted
- 2022-12-23
- Last updated
- 2023-06-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05663411. Inclusion in this directory is not an endorsement.